News | Patient Positioning Radiation Therapy | September 23, 2016

ZDi Introduces Z-System Patient Positioning Devices at ASTRO 2016

Moldable technology allows more precise, reproducible positioning during treatment planning and administration

ZDi Solutions, Z-System, radiation therapy, proton therapy, patient positioning, ASTRO 2016

September 23, 2016 — ZDi Solutions LLC announced that it will soon market its Z-System patient positioning devices to proton therapy and conventional radiation therapy facilities in the United States, with plans to collaborate worldwide. The system is comprised of the Z-Box, Z-Square and Z-Tilt. The team from ZDi will be attending the annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston Sept. 25-28 to demonstrate the technology.

The devices were developed by Zachary Dutton, R.T. (R)(T), chief design officer of ZDi, who saw a need for strong, lightweight, positioning devices. Dutton explained, "Although moldable technology has improved, it can be difficult to work with as therapists navigate the positioning bag and the patient. Several hands are needed to assist in complex cases involving the thoracic and abdominal regions. A device was needed that would take the place of those extra hands. Additionally, many of these setups present a challenge for patients who are unable to hold both arms above their head."  Dutton also factored the strength of the immobilization device into his design.

The Z-Box, the custom supportive piece of the Z-System, is a winged apparatus used during immobilization foam mold fabrication, most often during computed tomography (CT) simulation. The Z-Box is fully adjustable to any arm position and has side "wings" on the board which operate on a hinge that can be raised or lowered to the desired height to fully support the patient's arms. The adjustable extension under the hands and forearms can be locked in to the appropriate height. These adjustments not only support the patient in a comfortable position but also create a deep mold for the cradle. This deep mold provides an accurate casting around the patient's arms. This exact reproducibility of the arm position is one of the most important factors in treatment alignment for proton therapy.

ZDi has successfully tested the device at the Provision Center for Proton Therapy in Knoxville, Tenn.

For more information: www.zdirad.com

Related Content

Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes

Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes. The metallic-based nanoparticles show up on CT scans so it can be used as a permanent fiduciary marker to track tumor response. The images show the initial tumor and enhancement areas due to the nanoparticles and the resulting outcomes following treatment. Photo by Dave Fornell

Feature | Radiation Oncology | January 30, 2019 | By Dave Fornell
Artificial intelligence (AI) has been the hot topic discussed at all trade shows, and the...
Videos | Lung Cancer | January 29, 2019
Gregory Videtic, M.D., staff physician in radiation oncology at the Cleveland Clinic, and David Johnstone, M.D., prof
Southern Asia's First Proton Therapy Center Begins Treatments
News | Proton Therapy | January 28, 2019
IBA (Ion Beam Applications SA) announced the opening of the Apollo Proton Cancer Centre in Chennai, India, and the...